Targeted gene therapy for breast cancer with truncated Bid

Cancer Gene Therapy

Volumn 13, Issue 2, 2006, Pages 141-149

  Kazhdan, I ^a,c   Long, L ^a   Montellano, R ^a   Cavazos, D A ^a   Marciniak, R A ^a,b  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Breast cancer; tBid; Tumor targeting

Indexed keywords

DEATH RECEPTOR; MUCIN 1; PROTEIN BID; SURVIVIN; TELOMERASE REVERSE TRANSCRIPTASE; VIRUS VECTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CELL KILLING; CONTROLLED STUDY; CYTOMEGALOVIRUS VECTOR; GENE CONSTRUCT; GENE TARGETING; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RECEPTOR INTRINSIC ACTIVITY; VIRAL GENE DELIVERY SYSTEM;

ANTIGENS, NEOPLASM; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CYTOMEGALOVIRUS; DNA PRIMERS; DNA-BINDING PROTEINS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GENE THERAPY; GENETIC VECTORS; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; MUCINS; NEOPLASM PROTEINS; PROMOTER REGIONS (GENETICS); TELOMERASE; TRANSFECTION;

CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS;

EID: 30944451367     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700867     Document Type: Article

References (55)

1. Ferreira CG, Span SW, Peters GJ, Kruyt FA, Giaccone G. Chemotherapy triggers apoptosis in a caspase-8-dependent and mitochondria-controlled manner in the non-small cell lung cancer cell line NCI-H460. Cancer Res 2000; 60: 7133-7141.
2. Bold RJ, Termuhlen PM, McConkey DJ. Apoptosis, cancer and cancer therapy. Surg Oncol 1997; 6: 133-142.
3. Madesh M, Antonsson B, Srinivasula SM, Alnemri ES, Hajnoczky G. Rapid kinetics of tBid-induced cytochrome c and Smac/DIABLO release and mitochondrial depolarization. J Biol Chem 2002; 277: 5651-5659.
4. Velculescu VE, Madden SL, Zhang L, Lash AE, Yu J, Rago C et al. Analysis of human transcriptomes. Nat Genet 1999; 23: 387-388.
5. Adida C, Berrebi D, Peuchmaur M, Reyes-Mugica M, Altieri DC. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet 1998; 351: 882-883.
6. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3: 917-921.
7. Andersen MH, Thor SP. Survivin - a universal tumor antigen. Histol Histopathol 2002; 17: 669-675.
8. Monzo M, Rosell R, Felip E, Astudillo J, Sanchez JJ, Maestre J et al. A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol 1999; 17: 2100-2104.
9. Azuhata T, Scott D, Takamizawa S, Wen J, Davidoff A, Fukuzawa M et al. The inhibitor of apoptosis protein survivin is associated with high-risk behavior of neuroblastoma. J Pediatr Surg 2001; 36: 1785-1791.
10. Sarela AI, Macadam RC, Farmery SM, Markham AF, Guillou PJ. Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut 2000; 46: 645-650.
11. Adida C, Haioun C, Gaulard P, Lepage E, Morel P, Briere J et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 2000; 96: 1921-1925.
12. Kato J, Kuwabara Y, Mitani M, Shinoda N, Sato A, Toyama T et al. Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer 2001; 95: 92-95.
13. Endoh A, Asanuma K, Moriai R, Yamada M, Koyanagi Y, Sato T et al. Expression of survivin mRNA in CD34-positive cells. Clin Chim Acta 2001; 306: 149-151.
14. Kobayashi Y, Yukiue H, Sasaki H, Fukai I, Yokoyama T, Kiriyama M et al. Developmentally regulated expression of survivin in the human thymus. Hum Immunol 2002; 63: 101-107.
15. Gianani R, Jarboe E, Orlicky D, Frost M, Bobak J, Lehner R et al. Expression of survivin in normal, hyperplastic, and neoplastic colonie mucosa. Hum Pathol 2001; 32: 119-125.
16. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 2000; 6: 127-134.
17. Chen JS, Liu JC, Shen L, Rau KM, Kuo HP, Li YM et al. Cancer-specific activation of the survivin promoter and its potential use in gene therapy. Cancer Gene Ther 2004; 11: 740-747.
18. Zhu ZB, Makhija SK, Lu B, Wang M, Kaliberova L, Liu B et al. Transcriptional targeting of tumors with a novel tumor-specific survivin promoter. Cancer Gene Ther 2004; 11: 256-262.
19. Yang L, Cao Z, Li F, Post DE, Van Meir EG, Zhong H et al. Tumor-specific gene expression using the survivin promoter is further increased by hypoxia. Gene Therapy 2004; 11: 1215-1223.
20. Hiyama E, Hiyama K. Clinical utility of telomerase in cancer. Oncogene 2002; 21: 643-649.
21. Kyo S, Takakura M, Inoue M. Telomerase activity in cancer as a diagnostic and therapeutic target. Histol Histopathol 2000; 15: 813-824.
22. Lehner R, Enomoto T, McGregor JA, Shroyer AL, Haugen BR, Pugazhenthi U et al. Quantitative analysis of telomerase hTERT mRNA and telomerase activity in endometrioid adenocarcinoma and in normal endometrium. Gynecol Oncol 2002; 84: 120-125.
23. Paradis V, Bieche I, Dargere D, Bonvoust F, Ferlicot S, Olivi M et al. hTERT expression in sporadic renal cell carcinomas. J Pathol 2001; 195: 209-217.
24. Kyo S, Inoue M. Complex regulatory mechanisms of telomerase activity in normal and cancer cells: how can we apply them for cancer therapy? Oncogene 2002; 21: 688-697.
25. Gu J, Andreeff M, Roth JA, Fang B. hTERT promoter induces tumor-specific Bax gene expression and cell killing in syngenic mouse tumor model and prevents systemic toxicity. Gene Therapy 2002; 9: 30-37.
26. Gu J, Kagawa S, Takakura M, Kyo S, Inoue M, Roth JA et al. Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers. Cancer Res 2000; 60: 5359-5364.
27. Koga S, Hirohata S, Kondo Y, Komata T, Takakura M, Inoue M et al. FADD gene therapy using the human telomerase catalytic subunit (hTERT) gene promoter to restrict induction of apoptosis to tumors in vitro and in vivo. Anticancer Res 2001; 21: 1937-1943.
28. Komata T, Kondo Y, Kanzawa T, Hirohata S, Koga S, Sumiyoshi H et al. Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter. Cancer Res 2001; 61: 5796-5802.
29. Kufe D, Inghirami G, Abe M, Hayes D, Justi-Wheeler H, Schlom J. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma 1984; 3: 223-232.
30. Ohuchi N, Page DL, Merino MJ, Viglione MJ, Kufe DW, Schlom J. Expression of tumor-associated antigen (DF3) in atypical hyperplasias and in situ carcinomas of the human breast. J Natl Cancer Inst 1987; 79: 109-117.
31. Chen L, Chen D, Manome Y, Dong Y, Fine HA, Kufe DW. Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter. J Clin Invest 1995; 96: 2775-2782.
32. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 2002; 277: 3247-3257.
33. Kazhdan I, Marciniak RA. Death receptor 4 (DR4) efficiently kills breast cancer cells irrespective of their sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Cancer Gene Ther 2004; 11: 691-698.
34. Gu J, Andreeff M, Roth JA, Fang B. hTERT promoter induces tumor-specific Bax gene expression and cell killing in syngenic mouse tumor model and prevents systemic toxicity. Gene Therapy 2002; 9: 30-37.
35. Tai YT, Strobel T, Kufe D, Cannistra SA. In vivo cytotoxicity of ovarian cancer cells through tumor-selective expression of the BAX gene. Cancer Res 1999; 59: 2121-2126.
36. Bao R, Connolly DC, Murphy M, Green J, Weinstein JK, Pisarcik DA et al. Activation of cancer-specific gene expression by the survivin promoter. J Natl Cancer Inst 2002; 94: 522-528.
37. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 2000; 6: 127-134.
38. Hanson JM, Browell DA, Cunliffe WJ, Varma J, Allen A, Hemming D et al. MUC1 expression in primary breast cancer: the effect of tamoxifen treatment. Breast Cancer Res Treat 2001; 67: 215-222.
39. Kimura M, Koida T, Yanagita Y. A study on telomerase activity and prognosis in breast cancer. Med Oncol 2003; 20: 117-126.
40. Mueller C, Riese U, Kosmehl H, Dahse R, Claussen U, Ernst G. Telomerase activity in microdissected human breast cancer tissues: association with p53, p21 and outcome. Int J Oncol 2002; 20: 385-390.
41. Zhao J, Tenev T, Martins LM, Downward J, Lemoine NR. The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. J Cell Sci 2000; 113(Part23): 4363-4371.
42. Wang S, Zhu J. Evidence for a relief of repression mechanism for activation of the human telomerase reverse transcriptase promoter. J Biol Chem 2003; 278: 18842-18850.
43. Cong YS, Bacchetti S. Histone deacetylation is involved in the transcriptional repression of hTERT in normal human cells. J Biol Chem 2000; 275: 35665-35668.
44. Guilleret I, Yan P, Grange F, Braunschweig R, Bosman FT, Benhattar J. Hypermethylation of the human telomerase catalytic subunit (hTERT) gene correlates with telomerase activity. Int J Cancer 2002; 101: 335-341.
45. Wu KJ, Grandori C, Amacker M, Simon-Vermot N, Polack A, Lingner J et al. Direct activation of TERT transcription by c-MYC. Nat Genet 1999; 21: 220-224.
46. Rummukainen J, Kytola S, Karhu R, Farnebo F, Larsson C, Isola JJ. Aberrations of chromosome 8 in 16 breast cancer cell lines by comparative genomic hybridization, fluorescence in situ hybridization, and spectral karyotyping. Cancer Genet Cytogenet 2001; 126: 1-7.
47. Lin T, Gu J, Zhang L, Huang X, Stephens LC, Curley SA et al. Targeted expression of green fluorescent protein/tumor necrosis factor-related apoptosis-inducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effects on primary human hepatocytes. Cancer Res 2002; 62: 3620-3625.
48. Johnson AL, Langer JS, Bridgham JT. Survivin as a cell cycle-related and antiapoptotic protein in granulosa cells. Endocrinology 2002; 143: 3405-3413.
49. Otaki M, Hatano M, Kobayashi K, Ogasawara T, Kuriyama T, Tokuhisa T. Cell cycle-dependent regulation of TIAP/m-survivin expression. Biochim Biophys Acta 2000; 1493: 188-194.
50. Lebeau J, Fouchet P, Ory K, Chevillard S. Down-regulation of telomerase activity after progesterone treatment of human breast cancer cells: essential role of the cell cycle status. Anticancer Res 2002; 22: 2161-2166.
51. Li F, Altieri DC. Transcriptional analysis of human survivin gene expression. Biochem J 1999; 344(Part 2): 305-311.
52. Sommer KW, Schamberger CJ, Schmidt GE, Sasgary S, Cerni C. Inhibitor of apoptosis protein (IAP) survivin is upregulated by oncogenic c-H-Ras. Oncogene 2003; 22: 4266-4280.
53. Hanson JM, Browell DA, Cunliffe WJ, Varma J, Allen A, Hemming D et al. MUC1 expression in primary breast cancer: the effect of tamoxifen treatment. Breast Cancer Res Treat 2001; 67: 215-222.
54. Kami K, Doi R, Koizumi M, Toyoda E, Mori T, Ito D et al. Survivin expression is a prognostic marker in pancreatic cancer patients. Surgery 2004; 136: 443-448.
55. Groot-Wassink T, Aboagye EO, Wang Y, Lemoine NR, Keith WN, Vassaux G. Noninvasive imaging of the transcriptional activities of human telomerase promoter fragments in mice. Cancer Res 2004; 64: 4906-4911.